Robert G. Alberstein

Angelica Chen, Samuel D. Stanton, Frances Ding et al.

Although large language models (LLMs) have shown promise in biomolecule optimization problems, they incur heavy computational costs and struggle to satisfy precise constraints. On the other hand, specialized solvers like LaMBO-2 offer efficiency and fine-grained control but require more domain expertise. Comparing these approaches is challenging due to expensive laboratory validation and inadequate synthetic benchmarks. We address this by introducing Ehrlich functions, a synthetic test suite that captures the geometric structure of biophysical sequence optimization problems. With prompting alone, off-the-shelf LLMs struggle to optimize Ehrlich functions. In response, we propose LLOME (Language Model Optimization with Margin Expectation), a bilevel optimization routine for online black-box optimization. When combined with a novel preference learning loss, we find LLOME can not only learn to solve some Ehrlich functions, but can even perform as well as or better than LaMBO-2 on moderately difficult Ehrlich variants. However, LLMs also exhibit some likelihood-reward miscalibration and struggle without explicit rewards. Our results indicate LLMs can occasionally provide significant benefits, but specialized solvers are still competitive and incur less overhead.

Frédéric A. Dreyer, Jan Ludwiczak, Karolis Martinkus et al.

We introduce Ibex, a pan-immunoglobulin structure prediction model that achieves state-of-the-art accuracy in modeling the variable domains of antibodies, nanobodies, and T-cell receptors. Unlike previous approaches, Ibex explicitly distinguishes between bound and unbound protein conformations by training on labeled apo and holo structural pairs, enabling accurate prediction of both states at inference time. Using a comprehensive private dataset of high-resolution antibody structures, we demonstrate superior out-of-distribution performance compared to existing specialized and general protein structure prediction tools. Ibex combines the accuracy of cutting-edge models with significantly reduced computational requirements, providing a robust foundation for accelerating large molecule design and therapeutic development.

Ada Fang, Robert G. Alberstein, Simon Kelow et al.

The complementarity-determining regions of antibodies are loop structures that are key to their interactions with antigens, and of high importance to the design of novel biologics. Since the 1980s, categorizing the diversity of CDR structures into canonical clusters has enabled the identification of key structural motifs of antibodies. However, existing approaches have limited coverage and cannot be readily incorporated into protein foundation models. Here we introduce ImmunoGlobulin LOOp Tokenizer, Igloo, a multimodal antibody loop tokenizer that encodes backbone dihedral angles and sequence. Igloo is trained using a contrastive learning objective to map loops with similar backbone dihedral angles closer together in latent space. Igloo can efficiently retrieve the closest matching loop structures from a structural antibody database, outperforming existing methods on identifying similar H3 loops by 5.9\%. Igloo assigns tokens to all loops, addressing the limited coverage issue of canonical clusters, while retaining the ability to recover canonical loop conformations. To demonstrate the versatility of Igloo tokens, we show that they can be incorporated into protein language models with IglooLM and IglooALM. On predicting binding affinity of heavy chain variants, IglooLM outperforms the base protein language model on 8 out of 10 antibody-antigen targets. Additionally, it is on par with existing state-of-the-art sequence-based and multimodal protein language models, performing comparably to models with $7\times$ more parameters. IglooALM samples antibody loops which are diverse in sequence and more consistent in structure than state-of-the-art antibody inverse folding models. Igloo demonstrates the benefit of introducing multimodal tokens for antibody loops for encoding the diverse landscape of antibody loops, improving protein foundation models, and for antibody CDR design.